Clinical pharmacology of the fluoroquinolones: Studies in human dynamic/kinetic models

被引:73
作者
Schentag, JJ
机构
[1] SUNY Buffalo, Millard Fillmore Hosp, Sch Pharm, Buffalo, NY 14209 USA
[2] SUNY Buffalo, Millard Fillmore Hosp, Clin Pharmacokinet Lab, Buffalo, NY 14209 USA
关键词
D O I
10.1086/314059
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Traditional antibiotic dosage adjustments, compensate only for disease-induced changes in the serum concentration profile. Dosage adjustments tend to be effective when a well-defined range of concentration is associated with efficacy. However, the bacterial target of antibiotic action-minimum inhibitory concentration (MIC) is variable, because even susceptible bacteria may differ greatly in their antibiotic susceptibility. Newly developed computerized methods for the quantitation of susceptibility allow for testing of integrated kinetic-susceptibility models in patients. Our attention has focused on fluoroquinolones, since they are relatively nontoxic and provide the necessary dosage range needed to elucidate correlations between concentration and response. Studies of patients with nosocomial gram-negative pneumonia reveal that the best correlation parameters of favorable outcome are similar to 80% of time over MIC and 24-h area under the time-concentration curve (AUC)-to-MIC values >125.
引用
收藏
页码:S40 / S44
页数:5
相关论文
共 21 条
[1]   Pharmacodynamics of fluoroquinolones in experimental models of endocarditis [J].
Andes, DR ;
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (01) :47-50
[2]  
Bédos JP, 1998, J PHARMACOL EXP THER, V286, P29
[3]  
Blondeau JM, 1999, CLIN THER, V21, P3
[4]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[5]  
den Hollander JG, 1998, ANTIMICROB AGENTS CH, V42, P377
[6]  
Drusano GL, 1997, J CHEMOTHERAPY, V9, P38
[7]   PHARMACODYNAMICS AND PHARMACOKINETICS OF ANTIBIOTICS WITH SPECIAL REFERENCE TO THE FLUOROQUINOLONES [J].
DUDLEY, MN .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 :S45-S50
[8]   Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis [J].
Forrest, A ;
Chodosh, S ;
Amantea, MA ;
Collins, DA ;
Schentag, JJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 :45-57
[9]   PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
GOSS, TF ;
BIRMINGHAM, MC ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081
[10]   MATHEMATICAL EXAMINATION OF DUAL INDIVIDUALIZATION PRINCIPLES .2. THE RATE OF BACTERIAL ERADICATION AT THE SAME AREA UNDER THE INHIBITORY CURVE IS MORE RAPID FOR CIPROFLOXACIN THAN FOR CEFMENOXIME [J].
GOSS, TF ;
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
BIRMINGHAM, MC ;
CUMBO, TJ ;
SCHENTAG, JJ .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (7-8) :863-868